Pursuing a New Target for Autoimmune Diseases

Kezar Life Sciences is developing therapies for immune-mediated disorders and cancer. It’s lead experimental therapy is in development for the rare autoimmune condition lupus nephritis. It is a first-in-class therapy that targets master regulators of cellular function. We spoke to Noreen Henig, chief medical officer for Kezar, about lupus nephritis, the company first-in-class candidate to target the condition, and why it may have application in a broad range of autoimmune diseases.

Episode metadata supplied by the publisher feed · Published Oct 8, 2020

Embed this episode

Attribution link and audio player

What this episode covers

Noreen Henig, chief medical officer for Kezar Life Sciences, discusses lupus nephritis, the company’s first-in-class candidate to target the condition, and why it may have application in a range of autoimmune conditions.

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Pursuing a New Target for Autoimmune Diseases

0:00 20:04

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of RARECast?

This episode is 20 minutes long.

When was this RARECast episode published?

This episode was published on October 8, 2020.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!